Integrated DNA Technologies Acquires Synthegen
News Feb 02, 2006
Illustrating its commitment to continued growth, this latest acquisition by Coralville, Iowa based IDT further expands the company’s expertise in the synthesis of modified oligonucleotides.
The acquisition of Synthegen follows IDT’s recent purchase of San Diego, CA based GenBase, Inc. and the opening of the company’s first satellite production center.
"Synthegen has developed significant skills and abilities that target the specialty oligo market," said Integrated DNA Technologies, Inc. COO Trey Martin.
"This acquisition allows us to merge that expertise with IDT’s industry-leading quality and QC systems."
"It also brings the Synthegen product range to a wider market, and ensures that our customers continue to benefit from the widest selection, highest service level, and most reliable and consistent delivery of custom oligos available anywhere."
"Our success over the last 10 years clearly played a central role in the development of this deal," said David Colvin, president of Synthegen.
"And as our customer segment is smaller and more specialized than IDT’s, we were delighted to discover that they share our belief that the customer is the most important part of what we do."
"We know that the needs of our clients will be well served, and that this deal will deliver significant benefits for them."
Colvin is working with Integrated DNA Technologies, Inc. to support the seamless transition of the Synthegen product line into IDT’s portfolio.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.